FIZE Medical announced the first close of its Series B on September 17, with Asahi Kasei Medical and Rapha Capital Management co-leading the financing. The company is targeting $20 million for the round; its release does not disclose the amount secured at the initial close.
The investment accompanies a wider distribution relationship with Asahi Kasei Medical. Already FIZE's exclusive partner in Japan, the company will also distribute its kUO fluid-monitoring system in Europe.
FIZE plans to use the financing to strengthen commercial operations and develop FIZE Optima, a platform intended to use continuous patient data to predict fluid-related risks and support clinical decisions. The proposed predictive capabilities remain under development.